Skip to main content
. 2014 May 21;3(4):835–844. doi: 10.1002/cam4.262

Figure 3.

Figure 3

OS and FGFR3 staining in primary and metastatic tumors. (A) FGFR3 staining was not associated with a difference in OS in the primary tumor cohort (= 0.89). (B) FGFR3 staining was not associated with differences in OS from time of disease recurrence in the metastatic tumor cohort (= 0.78).